Idacio

Adalimumab, the active ingredient in Idacio, is a TNF‑alpha inhibitor presented as a 40 mg/0.8 mL solution for injection, prefilled syringe for subcutaneous use. It reduces inflammatory activity in autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

GNH USA supplies Idacio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Distribution is managed through a global network of vetted partners to ensure timely delivery.

Idacio (adalimumab) is a TNF‑alpha inhibitor used to control inflammation in several immune‑mediated diseases.

- Rheumatoid arthritis: reduces joint swelling, pain and slows structural damage. - Psoriatic arthritis: alleviates joint inflammation and skin lesions. - Ankylosing spondylitis: improves spinal mobility and reduces pain. - Crohn’s disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Plaque psoriasis: clears skin plaques and reduces scaling.

Adalimumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site reactions: pain, redness, swelling, or itching at the injection site. - Upper respiratory infections: mild cold‑like symptoms such as sore throat, sinus congestion, or cough. - Headache: transient mild to moderate headache occurring shortly after dosing. - Nausea: occasional feeling of stomach upset without vomiting.

Serious or Rare Side Effects: - Serious infections: tuberculosis, bacterial sepsis, or opportunistic fungal infections that may be life‑threatening. - Malignancies: increased risk of lymphoma, skin cancers including melanoma, and other solid tumors. - Autoimmune disorders: development of lupus‑like syndrome, vasculitis, or demyelinating diseases such as multiple sclerosis.

When prescribing Idacio, clinicians should observe several safety precautions to minimize risks.

- Infection screening: evaluate patients for active tuberculosis, hepatitis B/C and other infections before starting therapy. - Vaccination status: administer required live vaccines at least 4 weeks prior to the first dose; avoid live vaccines during treatment. - Heart failure monitoring: assess for worsening congestive heart failure and discontinue if symptoms exacerbate. - Laboratory monitoring: perform baseline and periodic CBC, liver enzymes, and lipid profile to detect hematologic or hepatic changes. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss uncertainties with the patient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the prefilled syringe.

Adalimumab can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid administering live vaccines while on therapy. - Antifungal or anti‑TB agents: concomitant use may increase risk of serious infections; require careful assessment.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., azathioprine, methotrexate): may enhance immunosuppression, requiring infection monitoring. - Cytochrome P450 substrates: adalimumab does not significantly affect CYP enzymes, but disease state may alter drug levels; monitor clinical response. - Interferon‑beta: combined use may increase risk of autoimmune phenomena; observe for new symptoms.